Hashimoto Dai, Nagata Toshi, Uchijima Masato, Seto Shintaro, Suda Takafumi, Chida Kingo, Miyoshi Hiroyuki, Nakamura Hirotoshi, Koide Yukio
Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Higashi-ku, Handa-yama, Hamamatsu 431-3192, Japan.
Vaccine. 2008 Sep 19;26(40):5095-100. doi: 10.1016/j.vaccine.2008.03.101. Epub 2008 May 7.
The present study evaluates the potential of improved third-generation lentivirus vector with respect to their use as an in vivo-administered T-cell vaccine against tuberculosis. Intratracheal administration of the lentivirus vector encoding MPT51 of Mycobacterium tuberculosis could induce MPT51-specific CD8+ T cells in the mediastinal lymph nodes 2 weeks after the administration. The vaccination could generate MPT51-specific memory CD8+ T cells in the lung, but not in the lymph nodes. Further, a single intratracheal immunization of MPT51 lentiviral vaccine decreased significantly the number of virulent M. tuberculosis in the lung after intratracheal challenge of the bacillus. These findings suggest that intratracheal immunization of the third-generation lentiviral vaccines is a promising vaccination strategy against pulmonary tuberculosis.
本研究评估了改良的第三代慢病毒载体作为体内施用的抗结核T细胞疫苗的潜力。气管内施用编码结核分枝杆菌MPT51的慢病毒载体可在给药后2周在纵隔淋巴结中诱导产生MPT51特异性CD8 + T细胞。该疫苗接种可在肺部而非淋巴结中产生MPT51特异性记忆CD8 + T细胞。此外,单次气管内免疫MPT51慢病毒疫苗可显著减少在气管内接种毒力结核分枝杆菌后肺内的毒力结核分枝杆菌数量。这些发现表明,气管内免疫第三代慢病毒疫苗是一种有前景的抗肺结核疫苗接种策略。